Shionogi’s IDWeek 2026 data highlight cefiderocol susceptibility in resistant Pseudomonas aeruginosa, real-world clinical responses and evidence gaps in Gram-negative infections.
Written By: Malavatu Satvika, PharmD
Reviewed By: Pharmacally Editorial Team
Shionogi presented three evidence updates at IDWeek 2026 evaluating cefiderocol (Fetroja/Fetcroja), a siderophore cephalosporin used for certain susceptible Gram-negative infections. The findings cover real-world treatment outcomes, laboratory susceptibility in Pseudomonas aeruginosa ventilator-associated pneumonia (VAP) isolates, and published clinical experience in Stenotrophomonas maltophilia infections. Each addresses a different clinical question, and none independently establishes comparative treatment superiority.
PROVE: Lower Response After Antibiotic Failure
The international PROVE retrospective chart review included more than 1,000 patients treated between November 2020 and July 2024 in the United States and Europe. Its U.S. respiratory-infection subgroup included 266 patients, of whom 238 (89.5%) had carbapenem-resistant infections. The population was seriously ill: 74.8% were in intensive care, 65.4% received organ support and/or mechanical ventilation, and median hospital stay was 42 days.
Overall clinical response was 76.7% (204/266). Response was reported in 153/194 patients (78.9%) who received cefiderocol after pathogen identification and susceptibility results, 24/30 (80.0%) who received it empirically, and 26/41 (63.4%) who received it after a previous antibiotic regimen failed.
The 15.5-percentage-point difference between the first and salvage groups is clinically notable but does not establish that earlier cefiderocol treatment caused better outcomes. Patients receiving salvage therapy may have had more difficult infections or worsening illness. The empirical-treatment group’s 80.0% response rate also argues against interpreting the results as a simple ranking by treatment timing.
The reported subgroup denominators total 265 patients and the response numerators total 203, each one fewer than the corresponding overall total. Shionogi’s announcement does not explain these discrepancies. The findings support timely effective antimicrobial treatment as a clinical priority, but the independent effect of cefiderocol timing remains uncertain.
SENTRY: High Susceptibility Does Not Establish Clinical Benefit
The SENTRY surveillance analysis evaluated 1,400 P. aeruginosa VAP isolates collected in the United States and Europe during 2020–2024. Cefiderocol susceptibility was 99.5% by CLSI, 98.9% by EUCAST and 97.9% by FDA criteria.
Among isolates nonsusceptible to beta-lactam/beta-lactamase inhibitor (BL/BLI) combinations, 91.4%–96.0% remained susceptible under CLSI criteria. Among isolates carrying VIM, NDM or IMP metallo-beta-lactamase enzymes, comparator combinations generally showed susceptibility rates of 30.4%–41.8%.
These results indicate retained in-vitro activity against isolates for which some alternative antibiotics had limited activity. However, susceptibility rates depend on interpretive criteria and cannot directly predict survival, clinical cure or comparative effectiveness. The findings may help inform treatment selection when resistance restricts options, but clinical outcomes must be evaluated separately.
S. maltophilia: Clinical Evidence Remains Limited
A systematic literature review examined 45 published case reports and cohort studies involving cefiderocol treatment for S. maltophilia infections. Clinical response was reported in 35 of 49 patients described in case reports (71.4%).
This proportion is not a controlled efficacy estimate. Case reports and observational cohorts lack randomized comparators and may be affected by patient selection and publication bias. The findings provide additional clinical experience but cannot establish how cefiderocol compares with other treatment approaches.
Shionogi also noted that the Infectious Diseases Society of America’s 2026 antimicrobial-resistance guidance lists cefiderocol as a preferred treatment for invasive S. maltophilia infections. The guidance acknowledges that clinical outcome evidence remains limited and relies substantially on animal-model data.
Clinical Interpretation
The three evidence streams provide complementary but distinct information. PROVE describes observed outcomes in a severely ill real-world population, SENTRY demonstrates laboratory susceptibility against resistant isolates, and the literature review summarizes reported clinical experience in S. maltophilia infections.
Together, the findings support continued evaluation of cefiderocol in selected resistant Gram-negative infections. They do not establish universal effectiveness or comparative superiority. Prospective studies linking antimicrobial susceptibility, treatment timing and patient outcomes remain important for clarifying its clinical role.
References
Shionogi. IDWeek 2026: Shionogi Presents U.S. Analysis of Real-World Data Showing Early Treatment Initiation with Fetroja/Fetcroja (cefiderocol) Improved Clinical Outcomes in Patients with Respiratory Infections. October 21, 2026
Carr A, et al. Outcomes of Cefiderocol Treatment in U.S. Patients with Respiratory Tract Infections: Subgroup Analysis of the PROVE Observational Study. IDWeek 2026, poster #144.
Nguyen ST, et al. Cefiderocol Activity Across Highly Resistant Pseudomonas aeruginosa Ventilator-Associated Pneumonia Isolates: A Global Surveillance Study of SENTRY 2020–2024. IDWeek 2026, poster #459.
Martin A, et al. Systematic Literature Review of the Clinical Outcomes Associated with Cefiderocol Therapy for Stenotrophomonas maltophilia Infections. IDWeek 2026, poster #94.
About the Writer
Malavatu Satvika (Linkedin) is a Pharm.D professional and aspiring healthcare medical writer with clinical exposure and research experience. Her interests include medical writing, drug safety, pharmaceutical research, and evidence-based healthcare communication. She has contributed to two research publications in pharmaceutical journals and has gained practical experience in prescription review, patient counselling, medication review, adverse drug reaction monitoring, drug information services, literature review, and clinical documentation through regular hospital training.
She has completed certifications in clinical research, ICH-GCP E6(R3), data management for clinical research, and congenital hypothyroidism. With a strong foundation in pharmacy, clinical practice, and scientific research, she aims to translate complex medical and pharmaceutical information into accurate, clear, and evidence-based healthcare content. She is also preparing to pursue a PhD and further develop her expertise in medical writing and pharmaceutical research.